Guangzhou Wondfo Biotech has formed a JV with Biocartis Group of Belgium to commercialize Biocartis’ molecular diagnostics Idylla system in China. Wondfo provides medical diagnostic tests and testing equipment to global markets. The Idylla device is an automated, real-time Polymerase Chain Reaction (PCR) molecular diagnostics system, designed for clinical use. Biocartis and Wondfo will each own a 50% stake in the JV, which they will fund with a total of $16 million in equity.
Source: China Biotoday
